NEW YORK, September 24, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on the following
equities: CME Group Inc. (NASDAQ: CME), Commerce
Bancshares, Inc. (NASDAQ: CBSH), Conatus Pharmaceuticals
Inc. (NASDAQ: CNAT), Exelixis, Inc. (NASDAQ: EXEL),
CTI BioPharma Corp. (NASDAQ: CTIC). On Wednesday, September 23, 2015, NASDAQ ended at
4,752.74, down 0.08%, Dow Jones declined 0.31% to finish the day at
16,279.89, and the S&P closed at 1,938.76, down 0.20%. Register
for your complimentary reports at the links given below.
--
CME Group Inc.
--
CME Group Inc.'s stock edged higher by 0.58% to close
Wednesday's session at USD 91.24. The
stock recorded a trading volume of 0.67 million shares, which was
below its 50-day daily average volume of 1.65 million shares. Over
the last three days, CME Group Inc.'s shares have advanced 0.93%,
but in the past one week the stock has moved down 4.33%. On a
compounded total return basis, the stock has returned 0.09% in the
past one month, but has shown a negative return of 3.24% in the
past three months. The company is trading at a price to earnings
ratio of 25.85, compared to a historical PE ratio of 26.43.
Further, the stock is at a price to book ratio of 1.44, while the
historical PB ratio is near to 1.42. Additionally, the stock is
trading at a price to cash flow ratio of 18.60 and price to sales
ratio of 9.44. Sign up and read the free notes on CME at:
http://www.aciassociation.com/CME.pdf
--
Commerce Bancshares Inc.
--
The stock of Commerce Bancshares Inc. gained 0.91% to close
Wednesday's session at USD 44.48. A
trading volume of 0.65 million shares was recorded, which was
greater than its 150-day daily average volume of 0.53 million
shares. Over the last five days Commerce Bancshares Inc.'s shares
have declined by 1.48% and in the past one month the stock has lost
1.92%. The stock has returned 5.44% in the past six months and
4.28% in the last one year, on a compounded total return basis.
Further, the company is trading at a price to earnings ratio of
16.68 and at a price to book ratio of 1.92. Additionally, the stock
is trading at a price to cash flow ratio of 11.68 and price to
sales ratio of 3.75. Register for free on ACI Association and
access the latest research on CBSH at:
http://www.aciassociation.com/CBSH.pdf
--
Conatus Pharmaceuticals Inc.
--
Conatus Pharmaceuticals Inc.'s stock increased by 15.73% to
close Wednesday's session at USD
5.74. The company's shares fluctuated in the range of
USD 5.12 and USD 6.15. A total of 6.81 million shares
exchanged hands, which surpassed its 50-day daily average volume of
0.28 million shares and was above its 52-week average volume of
0.46 million shares. Over the last three days Conatus
Pharmaceuticals Inc.'s shares have advanced 23.71% and in the past
one week the stock has moved up 29.28%. The stock has returned
43.50% in the past one month but has shown a negative return of
2.05% in the last three months, on a compounded total return basis.
The company is trading at a market capitalization of USD 113.19 million. The complete research on CNAT
is available for free at:
http://www.aciassociation.com/CNAT.pdf
--
Exelixis Inc.
--
Exelixis Inc.'s stock added 0.16% to close Wednesday's session
at USD 6.25. The company's shares
oscillated between USD 6.09 and USD
6.33. The stock recorded a trading volume of 4.44 million
shares, which was above its 52-week average volume of 4.29 million
shares. Over the last five days Exelixis Inc.'s shares have
advanced 0.64% and in the past one month the stock has gained a
momentum of 19.05%. In addition, over the last three months the
stock has gained 62.76% and year to date the shares have picked up
334.03%. The company has returned 19.05% in the past one month and
293.08% in the past one year, on a compounded total return basis.
The company is trading with a market capitalization of USD 1,408.94 million. Additionally, the stock is
trading at a price to sales ratio of 45.41. Free in-depth research
on EXEL is available at:
http://www.aciassociation.com/EXEL.pdf
--
CTI BioPharma Corp
--
CTI BioPharma Corp's stock advanced 9.03% to close Wednesday's
session at USD 1.57. The share price
vacillated between USD 1.53 and USD
1.61. The stock recorded a trading volume of 2.52 million
shares, which was above its 50-day daily average volume of 1.16
million shares and above its 52-week average volume of 2.36 million
shares. Over the last three days CTI BioPharma Corp's shares have
advanced 3.97% and in the past one week the stock has moved up
1.29%. Moreover, in the last six months the stock has lost 17.80%
and year to date the shares have shed 33.47%. On a compounded total
return basis, the stock has shown a negative return of 19.07% in
the last half a year and of 40.08% in the past one year. Further,
the stock is trading at a price to sales ratio of 4.64. The
complimentary notes on CTIC can be downloaded in PDF format at:
http://www.aciassociation.com/CTIC.pdf
--
About ACI Association:
Active Charter Investors Association ("ACI Association")
produces regular sponsored and non-sponsored reports, articles,
stock market blogs, and popular investment newsletters covering
equities listed on NYSE and NASDAQ and micro-cap stocks. ACI
Association has two distinct and independent departments. One
department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ACI Association has not been compensated; directly or
indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on sound investment judgment and publicly
available information which is believed to be reliable. The
Reviewer and the Sponsor have not performed any independent
investigations or forensic audits to validate the information
herein. Unless otherwise noted, any content outside of this
document has no association with the Author, the Reviewer, or the
Sponsor (collectively referred to as the "Production Team") in any
way. The Production Team is compensated on a fixed monthly basis
and do not hold any positions of interest in any of the securities
mentioned herein. The information in this release has been
sourced from a third party data base.
NO WARRANTY
ACI Association, the Author, the Reviewer and the Sponsor
(collectively referred to as the "Publishers") are not responsible
for any error which may be occasioned at the time of printing of
this document or any error, mistake or shortcoming. No liability is
accepted by the Publishers whatsoever for any direct, indirect or
consequential loss arising from the use of this document. The
Publishers expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, the Publishers do not (1) guarantee the accuracy,
timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The
included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ACI Association nor any party affiliated
with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our
report(s), read our disclosures, or for more information, visit
http://www.aciassociation.com/.
RESTRICTIONS
ACI Association is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.aciassociation.com